胎儿染色体异常的筛查:ACOG实践简报第226号
本实践简报由ACOG制定,旨在提供胎儿染色体异常筛查试验的当前信息,回顾其获益、性能特征和局限性,并强调所有患者均应接受筛查和诊断试验的选择,且应在充分知情后自主决定是否检测。
要点
- 所有患者均应获得筛查和诊断试验的选择,并有权在咨询后接受或拒绝检测。
- 每次妊娠均应对患者进行胎儿染色体异常检测选择的咨询。
- 无单一筛查试验在所有情况下均优,需个体化咨询。
核心结论
- 胎儿染色体异常检测应基于充分准确的信息、患者临床情况、可及资源、价值观、兴趣和目标,成为知情患者的选择。
研究设计与样本
- 本实践简报由ACOG制定,基于现有文献回顾胎儿染色体异常筛查试验的获益、性能特征和局限性。
主要发现
- 产前筛查和诊断试验种类繁多,每种提供不同水平和性能的信息,各有相对优势和局限性。
- 无单一筛查试验在所有情况下均优,导致需要产科护理专业人员进行细致、以患者为中心的咨询,以及患者复杂的决策。
关键数值与推荐
- 所有患者均应获得筛查和诊断试验,所有患者有权在咨询后接受或拒绝检测。
- 每次妊娠均应对患者进行胎儿染色体异常检测选择的咨询。
临床怎么用
- 产科护理专业人员应准备讨论胎儿染色体异常的风险以及可用筛查和诊断试验的相对获益和局限性。
- 检测应基于充分准确的信息、患者临床情况、可及医疗资源、价值观、兴趣和目标,成为知情患者的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. A wide variety of prenatal screening and diagnostic tests are available; each offers varying levels of information and performance, and each has relative advantages and limitations. When considering screening test characteristics, no one test is superior in all circumstances, which results in the need for nuanced, patient-centered counseling from the obstetric care professional and complex decision making by the patient. Each patient should be counseled in each pregnancy about options for testing for fetal chromosomal abnormalities. It is important that obstetric care professionals be prepared to discuss not only the risk of fetal chromosomal abnormalities but also the relative benefits and limitations of the available screening and diagnostic tests. Testing for chromosomal abnormalities should be an informed patient choice based on provision of adequate and accurate information, the patient's clinical context, accessible health care resources, values, interests, and goals. All patients should be offered both screening and diagnostic tests, and all patients have the right to accept or decline testing after counseling.The purpose of this Practice Bulletin is to provide current information regarding the available screening test options available for fetal chromosomal abnormalities and to review their benefits, performance characteristics, and limitations. For information regarding prenatal diagnostic testing for genetic disorders, refer to Practice Bulletin No. 162, Prenatal Diagnostic Testing for Genetic Disorders. For additional information regarding counseling about genetic testing and communicating test results, refer to Committee Opinion No. 693, Counseling About Genetic Testing and Communication of Genetic Test Results. For information regarding carrier screening for genetic conditions, refer to Committee Opinion No. 690, Carrier Screening in the Age of Genomic Medicine and Committee Opinion No. 691, Carrier Screening for Genetic Conditions. This Practice Bulletin has been revised to further clarify methods of screening for fetal chromosomal abnormalities, including expanded information regarding the use of cell-free DNA in all patients regardless of maternal age or baseline risk, and to add guidance related to patient counseling.
引用
- Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226. Obstet Gynecol. 2020. PMID: 32804883. doi:10.1097/AOG.0000000000004084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。